Conmed (CNMD) Cash & Equivalents (2010 - 2026)

Conmed (CNMD) has reported Cash & Equivalents for 17 consecutive years, with $37.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash & Equivalents rose 10.0% year-over-year to $37.3 million; the trailing twelve-month figure through Jun 2026 stood at $37.3 million (up 10.0% YoY), and the FY2025 full-year result was $40.8 million, up 66.88% from the prior year.
• Cash & Equivalents improved to $37.3 million in Q2 2026 per CNMD's latest filing, from $35.0 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $53.2 million in Q2 2022 and bottomed at $24.3 million in Q4 2023.
• Historically, Cash & Equivalents has averaged $33.1 million across 5 years, with a median of $33.6 million in 2022.
• The sharpest annual moves came in 2023 and 2025: Cash & Equivalents tumbled 47.61% in 2023, then jumped 66.88% in 2025.
• Over 5 years, Cash & Equivalents stood at $28.9 million in 2022, then decreased by 16.05% to $24.3 million in 2023, then grew by 0.67% to $24.5 million in 2024, then surged by 66.88% to $40.8 million in 2025, then dropped by 8.55% to $37.3 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $37.3 million, $35.0 million, and $40.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.